EUCTR2005-005943-24-FI进行中（未招募）不适用
A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years. - HPV-011
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •All subjects must satisfy the following criteria at study entry:
- •Subjects who the investigator believes that they and/or their legally acceptable representative (LAR) can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •A male between, and including, 10 and 18 years of age at the time of the first vaccination.
- •Written informed consent obtained from the subject prior to enrolment
- •For subjects below the legal age of consent, a written informed consent must be obtained from the subject’s LAR. In addition, a written informed assent must be obtained from the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, >=0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. Day 0 - 29) any dose of vaccines. Administration of routine vaccines such as meningococcal, hepatitis A, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccines up to 8 days before any dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
- •Previous vaccination against Human Papillomavirus (HPV) or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
- •Previous vaccination administration of MPL or AS04 adjuvant.
- •Previous vaccination against Hepatitis B, known clinical history of Hepatitis B infection, or known exposure to Hepatitis B within the previous 6 weeks.
- •Cancer or autoimmune disease under treatment.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •Hypersensitivity to latex (found in syringe-tip cap and plunger).
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control (e.g. aluminium, MPL).
- •History of any neurologic disorders or seizures.
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature <37.5°C (99.5°F)/Axillary temperature <37.5°C (99.5°F).
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. Enrolment will be postponed until the subject is outside the specified window.
- •Concurrently participating in another clinical study, at any time during the study period (up to the Month 12 telephone contact), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
研究者
相似试验
进行中（未招募）
1 期
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adultsHealthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)EUCTR2020-004741-37-Outside-EU/EEAGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothersEUCTR2016-002733-30-FIGlaxoSmithKline Biologicals500
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothersEUCTR2016-002733-30-GBGlaxoSmithKline Biologicals500
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothersHealthy pregnant women (Respiratory Syncytial Virus)MedDRA version: 19.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-002733-30-ESGlaxoSmithKline S.A500
进行中（未招募）
1 期
A study to evaluate safety, reactogenicity, and immune response of GVGH iNTS TCV vaccine against invasive nontyphoidal Salmonella and Typhoid FeverHealthy volunteers (prevention of invasive nontyphoidal Salmonella disease and typhoid fever)EUCTR2021-005178-25-BEGlaxoSmithKline Biologicals SA155